Ovid Therapeutics Inc. · NASDAQ:OVID
Ovid Therapeutics — Investor Presentation (June 2021)
21 slides from Ovid Therapeutics's investor presentation, Jun 23, 2021
Slide 1: Ovid Therapeutics Corporate Overview
Ovid Therapeutics Corporate Overview June 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 1 January 2021 June 2021 Exhibit 99.1
Slide 2: Disclaimers and Forward-Looking Statements
Disclaimers and Forward-Looking Statements ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and s
Slide 3: Building the Next Major CNS Company
©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 3 On a mission to build a unique company that delivers first-in-class therapeutics for rare disorders of the CNS Building the Next Major CNS Company Clear Vision Enabled by a Strong Foundation June 2021 The Right Team, Experience and Track-Record +
Slide 4: Pipeline Focused on Advancing Treatment of Rare Diseases
Phase 3 Planned Initiation Mid-2021 Phase 3 Planned Initiation Mid-2021 Anticipate filing three INDs in three years, beginning 1H 2022 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 4 January 2021 June 2021 Pipeline Focused on Advancing Treatment of Rare Diseases
Slide 5: Up to $856M+ Agreement with Takeda (soticlestat)
5 June 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Up to $856M+ Agreement with Takeda (soticlestat) Regulatory Milestones Regulatory milestones Takeda initially funding two comprehensive pivotal trials (LGS and Dravet) Commercial Milestones/Royalties Commercial sales milestones post appr
Slide 6: Rare disease expertise helping overcome historical CNS challenges
©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 6 Our rare disease expertise coupled with recent scientific advances are helping overcome historical CNS challenges HISTORICAL CNS DRUG DEVELOPMENT CHALLENGES Incomplete understanding of disease biology Poor predictive value of animal models Lack of
Slide 7: Recent major scientific advances are driving a new wave of CNS therapeutics
Recent major scientific advances are driving a new wave of CNS therapeutics 7 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED June 2021 MULTIMODAL NEUROIMAGING HEADWAYS APPROACHES TO INTERACT WITH DNA / RNA BBB CROSSING ENABLED Recent successes in genetic medicine paves the path for next-gen ther
Slide 8: Advance Next-Generation Neuroscience Pipeline
Focus on ecosystem of rare neurological diseases with high unmet need Develop novel first-in-class / best-in-class therapeutics Create a customized disease approach leveraging deep understanding of underlying pathology Collaborate with the patient community, KOLs, and other external innovators to ac
Slide 9: OV329: Highly Potent Inhibitor of GABA Aminotransferase
OV329: Highly Potent Inhibitor of GABA Aminotransferase ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 9 June 23, 2021 Mechanism: Highly potent GABA aminotransferase (GABA-AT) oral small molecule inhibitor Development status: IND enabling studies are underway, IND expected 1H 2022 Opportunity: C
Slide 10: OV329 Appears Active in Models of Drug-Resistant Seizures
OV329 Appears Active in Models of Drug-Resistant Seizures ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 10 June 23, 2021 June 2021 NMDA Model described by Shi et al., 2014 (PMID 26600368) Orally delivered OV329 as effective as injectable SOC in infantile spasms model
Slide 11: OV882: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome
OV882: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome (AS) ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 11 June 23, 2021 June 2021 Mechanism: Short hairpin RNA that interacts with non-coding RNA to inhibit the silencing of paternal UBE3A gene Development status: POC* activit
Slide 12: OV882 Approach to the Treatment of Angelman Syndrome
OV882 Approach to the Treatment of Angelman Syndrome ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 12 June 23, 2021 June 2021 DESCRIPTION OF APPROACH BENEFITS AND DRAWBACKS RNAI APPROACHES TO TREATING ANGELMAN SYNDROME DISEASE STATE ASO APPROACH Angelman syndrome is caused by a mutation in the
Slide 13: OV882 Appears Active in AS Neuron Cell Model
OV882 Appears Active in AS Neuron Cell Model ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 13 June 23, 2021 June 2021 SCRAM shRNA OV882 UBE3A-ATS UBE3A mRNA Relative RNA Expression shRNA-OV882 Effects on UBE3A-Antisense and UBE3A Expression (iPSC-AS neurons) OV882 demonstrates activity in AS ne
Slide 14: OV815: Potential Advanced Genetic Therapy for KAND and Other KIF-associated Diseases
OV815: Potential Advanced Genetic Therapy for KAND and Other KIF-associated Diseases ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 14 June 23, 2021 June 2021 Mechanism: Genetic/molecular approach targeting KIF1A Development status: Currently in screening stage for aptamer and gene silencing tec
Slide 15: OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily
OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 15 June 23, 2021 KIF1A (Kinesin 3 Family Member) June 2021 Impact of KIF1A on neurotransmission KIF1A is a motor protein that transports cargo for neurons Disruption of car
Slide 16: Proven Business Development Strategy
Proven Business Development Strategy ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 16 June 23, 2021 June 2021 Monetized CNS expertise to strengthen the balance sheet and create a potential cash stream to build the next major player in CNS Successful track record of identifying promising targets
Slide 17: Targeting CNS Technology and Therapeutic Approaches
Targeting CNS Technology and Therapeutic Approaches 17 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Neuroscience Rare neurological, neurometabolic, ophthalmic, seizure related, other CNS disorders Actionable assets near IND or later Complementary to existing pipeline and strategy Leverage core
Slide 18: Strong Balance Sheet Supports Strategy
Strong Balance Sheet Supports Strategy ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 18 June 23, 2021 June 2021 Strong balance sheet: $233M in cash and cash equivalents as of 3/31/21 No further financial obligations for the development of soticlestat, significant downstream economics if soticle
Slide 19: Leadership Team With Required Track Record
©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 19 Jeremy Levin DPhil, MB Bchir Chairman, CEO Amit Rakhit MD, MBA President, CMO Jason Tardio MBA Chief Commercial Officer Jeffrey Rona Chief Business & Financial Officer Thomas Perone JD, MBA GC, Corporate Secretary, and CCO Leadership Team With Re
Slide 20: The Ingredients to Become a Major Player in Next CNS Wave
The Ingredients to Become a Major Player in Next CNS Wave 20 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED | CONFIDENTIAL June 23, 2021 Tackle, hard to treat CNS diseases avoided by others Use technology to achieve a fundamental change Leverage strong academic relationships Invest smart and con
Slide 21: Thank you
Thank you JUne 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED 21 January 2021 June 2021
Ovid Therapeutics — Investor Presentation (June 2021) on 6ix